Sign in
Taking peopleNo phase

Is a repeat fluid draw needed to treat spontaneous bacterial peritonitis?

Tests routine repeat belly fluid checks in spontaneous bacterial peritonitis.

Key facts

Who runs it
Chonnam National University Hospital
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Optimal Treatment Strategy for Spontaneous Bacterial Peritonitis
Status
Recruiting
People taking part
40 people, planned
Started
4 Oct 2026
Expected to end
31 Dec 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Routine Follow-up Paracentesis at 48 Hours
  • Other
Record updated
6 November 2026

Who can take part

The trial is looking for adults with liver cirrhosis who have spontaneous bacterial peritonitis, an infection of the fluid in the belly. It compares a routine repeat fluid test at about 48 hours with no routine repeat test.

Age
18 years or older
Sex
All sexes
Disease stage
Liver cirrhosis, shown by clinical, tissue or imaging findings, with spontaneous bacterial peritonitis.
Biomarker or test result
Belly fluid white cell (PMN) count of ≥250 cells/mm³ at the first fluid draw (paracentesis).
Main reasons for not taking part
  • Suspected peritonitis from another cause, such as a hole in the gut
  • Cannot safely have a fluid draw: platelet count <20,000/mm³ or PT-INR >3.0
  • Active bleeding or shock, or expected survival of less than 48 hours
  • Pregnancy or breastfeeding
  • Earlier culture showing resistance to cefotaxime or ceftriaxone
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Adults aged 18 years or older
  • Diagnosis of liver cirrhosis based on clinical, histologic, or imaging findings
  • Diagnosis of spontaneous bacterial peritonitis confirmed by an ascitic fluid polymorphonuclear leukocyte (PMN) count of ≥250 cells/mm³ at initial paracentesis
  • Ability and willingness to provide written informed consent

Who cannot take part

  • Previous ascitic fluid or blood culture demonstrating resistance to cefotaxime or ceftriaxone
  • Suspected secondary bacterial peritonitis, including suspected perforation of a gastrointestinal organ
  • Active bleeding or shock
  • Any other condition that, in the investigator's judgment, would prevent adherence to the study protocol
  • Inability to safely undergo paracentesis, defined as platelet count <20,000/mm³ or prothrombin time international normalized ratio (PT-INR) >3.0
  • Expected survival of less than 48 hours
  • Pregnancy or breastfeeding

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in South Korea.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Spontaneous bacterial peritonitis (SBP) is a serious infection that occurs in patients with liver cirrhosis and ascites and is associated with substantial morbidity and mortality. Current clinical practice often includes follow-up paracentesis approximately 48 hours after starting antibiotic treatment to assess the change in the ascitic fluid polymorphonuclear leukocyte (PMN) count. However, it remains uncertain whether routine follow-up paracentesis improves clinical outcomes compared with a strategy based primarily on clinical response.

Read full original descriptionShow less

This pilot randomized controlled trial will evaluate whether routine follow-up paracentesis is necessary in patients with cirrhosis and SBP. A total of 40 adult patients with SBP will be randomly assigned in a 1:1 ratio to either a routine follow-up paracentesis group or a no-routine follow-up paracentesis group. All participants will receive standard antibiotic therapy and intravenous albumin according to the study protocol.

Participants assigned to the routine follow-up paracentesis group will undergo repeat paracentesis approximately 48 hours after initiation of antibiotic therapy. Ascitic fluid PMN counts and other laboratory findings will be assessed, and antibiotic treatment may be modified according to the treatment response. Participants assigned to the no-routine follow-up paracentesis group will be monitored using clinical symptoms, vital signs, and blood inflammatory markers without scheduled repeat paracentesis. However, paracentesis may be performed at any time if clinically indicated, such as in the presence of worsening abdominal symptoms, persistent fever, or hemodynamic instability.

The study will compare clinical outcomes between the two treatment strategies, including 30-day and 90-day survival, treatment response, duration of antibiotic therapy, length of hospital stay, SBP recurrence, complications, new infections, and medical costs. The results of this pilot study are intended to provide preliminary evidence for determining whether routine follow-up paracentesis can be safely avoided in selected patients with SBP and to inform the design of a larger randomized controlled trial.

The 2 groups in the trial

  • A (Routine Follow-up Paracentesis)Treatment being tested

    Routine follow-up paracentesis approximately 48 hours after initiation of antibiotic therapy.

    Treatment: Routine Follow-up Paracentesis at 48 Hours

  • B (No Routine Follow-up Paracentesis)Existing treatment, for comparison

    No routine follow-up paracentesis; paracentesis will be performed only when clinically indicated.

    Treatment: Other

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomized Controlled Study of Optimal Treatment Strategy for Spontaneous Bacterial Peritonitis in Liver Cirrhosis: A Pilot Study
Plain-language title
Is a repeat fluid draw needed to treat spontaneous bacterial peritonitis?Generated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT07923318, who can take part
Record updated
6 November 2026